Sobi to review preclinical data to potentially add future haemophilia A candidate to collaboration agreement with Biogen Idec

On Friday, 13 June, Swedish Orphan Biovitrum AB's (publ) (Sobi) received a data
package from Biogen Idec regarding a preclinical Hemophilia A program based on
Amunix's proprietary XTEN technology. Amunix and Biogen Idec signed a worldwide
license agreement in April 2014. Under the terms of Sobi and Biogen Idec's
agreement, Sobi has the right to elect to obtain an option to add potential
additional Factor VIII:Fc Constructs to the collaboration. Sobi has 120 days to
review the preclinincal data, and to determine whether to elect to obtain such
option under the collaboration. If Sobi elects to aquire its option, the company
will be required to make a payment to Biogen Idec.

Biogen Idec and Sobi are collaborators in the development and commercialisation
of Eloctate and Alprolix for haemophilia A and B. Biogen Idec leads development,
has manufacturing rights, and has commercialisation rights in North America and
all other regions in the world excluding the Sobi territory. Sobi has the right
to opt in to assume final development and commercialisation in Europe, including
Russia, the Middle East and Northern Africa.

- - -

About Haemophilia A
Haemophilia A is a rare, chronic, genetic disorder in which the ability of a
person's blood to clot is impaired, due to missing or reduced levels of a
protein known as factor VIII. People with haemophilia A experience recurrent and
extended bleeding episodes that cause pain and irreversible joint damage. Some
of these bleeding episodes can be life-threatening. According to the World
Federation of Hemophilia, an estimated 142,000 people worldwide are identified
living with haemophilia A.[1] Prophylactic injections of factor VIII can
temporarily replace the clotting factor necessary to control bleeding and
prevent new bleeding episodes.

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
(€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.

For more information please contact
 Media relations                    Investor relations

 Charlotte af Klercker,             Jörgen Winroth,
 Senior Communications Manager      Vice President, Head of Investor Relations

 T: +46 707 297 327                  T: +1 347-224-0819, +1 212-579-0506,
                                    +46 8 697 2135

 charlotte.afklercker@sobi.com      jorgen.winroth@sobi.com



The above information was released for public distribution on 16 June 2014, at
08:00 CET.

--------------------------------------------------------------------------------

[1] World Federation of Hemophilia. Annual Global Survey 2012.
http://www1.wfh.org/publications/files/pdf-1574.pdf

[HUG#1793175]